Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 JUL 28 ... (BZDs) [alprazolam (APZ), clonazepam (CLZ), flunitrazepam (FLZ), loprazolam (LPZ), zolpidem (ZLP)], at two distinct doses, 0.2 and 2 mg/kg, on the cell surface regulation of ...
2009 SEP 21 ... Meda Pharmaceuticals Inc. (Meda) announced the commercial availability of EDLUAR™ (zolpidem tartrate sublingual tablets) in the United States. EDLUAR is indicated for the ...
2009 SEP 14 ... centers, has launched an ambitious research study to investigate how the sleep drug zolpidem might restore consciousness for patients in the vegetative state. Led by John Whyte, MD, ...
2009 NOV 16 ... States report. "The purpose of this study was to determine the effect of zolpidem on the sleep arousal mechanism and acid clearance in patients with documented GER, ...
2009 NOV 16 ... Application No. 10/671,715, entitled "Buccal, Polar and Non-polar Spray Containing Zolpidem," which covers a method of treating insomnia by administering...
2009 AUG 17 ... entry into an exclusive license and collaboration agreement to commercialize Intermezzo (zolpidem tartrate sublingual tablet) in the United States. If approved by the U.S. Food and Drug ...
2009 SEP 22 ... IPSCs recorded in LTS cells from deprived barrels show a marked increase in zolpidem sensitivity. To determine if the faster IPSC decay in LTS cells from deprived barrels ...
2009 AUG 31 ... phase IV, randomized, double-blind, parallel group, placebo-controlled trial of zolpidem tartrate extended-release taken in combination with escitalopram vs. placebo combined ...
2009 AUG 17 ... a double-blind study whereby subjects received placebo, caffeine (150 mg), caffeine plus zolpidem (10 mg) and caffeine plus trazodone (100 mg) at bedtime in a randomised crossover ...
2009 NOV 9 ... "Parallel controlled clinical trials of eszopiclone, ramelteon, zaleplon, and zolpidem were included when data on subjects, duration of exposure, and adverse effects were ...
2009 NOV 1 ... disorder). A dramatic improvement of symptoms was observed after oral administration of zolpidem. This case seems to confirm that catatonia can represents a nonspecific response to ...
2009 AUG 31 ... Collaboration Agreement with Purdue Pharmaceutical Products to commercialize Intermezzo (zolpidem tartrate sublingual tablet) in the United States. Glenn A. Oclassen, ...
2009 NOV 9 ... a Complete Response Letter regarding the New Drug Application (NDA) for Intermezzo=AE (zolpidem tartrate sublingual tablet). The NDA, submitted by Transcept in September 2008, seeks ...
2009 NOV 16 ... under U.S. patent application no. 11/833,323, which covers the use of Intermezzo=AE (zolpidem tartrate sublingual tablet), the lead Transcept product candidate. Once issued, this ...
2009 AUG 24 ... with Purdue Pharmaceutical Products, L.P. for the commercialization of Intermezzo (zolpidem tartrate sublingual tablet) in the United States has further strengthened our financial ...
2009 NOV 23 ... a Complete Response Letter regarding the New Drug Application (NDA) for Intermezzo=AE (zolpidem tartrate sublingual tablet), the lead Transcept product candidate. The NDA seeks ...
